Home
Site Map
Search:
About Us
Overview
Management
Collaborations & Contractors
Business Strategy
Investors
Products & Technology
Clinical Development Programs
Scientific Rationale
Intellectual property
Markets
Obesity
Antipsychotic drug induced weight gain
Newsroom
Press Releases
Media Coverage
Contact Us
About Us
Products & Technology
Markets
Newsroom
Contact Us
Press Releases
Media Coverage
Press Releases
22.02.2010
Obecure Is Granted Methods and Composition Patents Covering Adjunctive Use of Betahistine to Mitigate Weight Gain Associated With Olanzapine
16.02.2010
Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA
14.06.2009
Obecure announces successful clinical results for its lead drug to mitigate weight gain
23.04.2009
Completion of Phase II Clinical Trial - Evaluation of Safety and Efficacy of Histalean™ for Treatment of Obesity
05.04.2009
Completion of Clinical Trial BET209 - Evaluation of the Potential of Histalean™ for Attenuating Weight Gain In Women Taking Antipsychotic Drugs
23.02.2009
Initiation of New Trial - Prevention of Weight Gain in Women Taking Anti-Psychotic Medication
20.01.2009
Obecure Completes Patient Enrollment for Phase IIb Trial with Histalean™ in Obesity
08.09.2008
Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopause Women
04.05.2008
Obecure Signs Strategic Agreement with Farmaceutici-Formenti of the Grunenthal Group for Manufacturing and Supply of Betahistine in Europe
02.09.2007
Obecure Phase II Trial Shows Positive Results For Histalean™ In Obese Women Under 50
25.06.2007
Obecure Completes Treatment of Patients in Phase II Obesity Trial
16.05.2007
Obecure Initiates Phase II Study to Examine Effect of OBE101 on Plasma Lipids in Patients Treated With Simvastatin
<< < |
1
|
2
|
>
>>
Total Pages: 2
©2007 All Rights Reserved to Obecure Ltd.
Disclaimer
Created by
Virtual Point Ltd.